eXoZymes announces role in $9.2M Meta-PURE initiative
eXoZymes' Role in Meta-PURE Initiative: eXoZymes is participating in the $9.2M Meta-PURE project, funded by the National Science Foundation, aimed at enhancing cell-free biomanufacturing through standardized modules for various applications, including nutraceuticals and pharmaceuticals.
Innovative Cell-Free Power Module: The company will develop an ATP-generating module that allows for faster production and higher yields by decoupling power from production processes, facilitating easier access for partners in synthetic biology.
Trade with 70% Backtested Accuracy
Analyst Views on EXOZ
About EXOZ
About the author
Monday 7/7 Insider Buying Report: EXOZ, IAF
Insider Purchases: CEO Michael Heltzen of Exozymes purchased 1,040 shares at $10.22 each, while Director Moritz A. Sell bought $9,000 worth of Aberdeen Australia Equity Fund shares at $4.50 each, marking their first purchases in the past year.
Stock Performance: Exozymes stock is currently trading lower than Heltzen's purchase price, while Aberdeen Australia Equity Fund has seen a slight decline of 0.9% on the same day.
Bringing clarity and precision to the cell-free space by introducing exozymes
Introduction of Exozymes: The term 'exozymes' has been introduced in a cover story published in GEN Biotechnology to clarify the concept of cell-free biomanufacturing, which allows for chemical production without living cells. This initiative aims to foster innovation and streamline partnerships in the field.
eXoZymes Inc. Overview: eXoZymes Inc., a pioneer in AI-engineered enzymes, is leading the development of sustainable biomanufacturing methods that replace traditional chemical processes with eco-friendly alternatives, enhancing the scalability and efficiency of producing essential chemicals and medicines.
